Sunday, March 22, 2026

 

Can DNA be used to build robots?


Scientists bridge the gap between macro-scale robotics and the molecular world to build programmable "intelligent" robots at the nanoscale.





Journal Center of Harbin Institute of Technology

Designer DNA-Based Machines 

video: 

Robotics and DNA nanotechnology converge to create dynamic systems capable of intelligent, adaptable functions. These DNA machines could play pivotal roles in biomedicine, single-molecule analysis, atomic-scale nanofabrication, and DNA-based computing and data storage, pushing the boundaries of what is possible in robotics.

view more 

Credit: SmartBot




The Potential of DNA as a Building Block for Nanomachines

Imagine DNA robots traveling through the bloodstream to deliver drugs, targeting specific cells like cancer or viruses. These molecular machines could even build advanced data storage and computing devices with nanometer precision. While these robots hold immense potential, most of them are still in the experimental phase, more proof of concept than practical tool.

 

In this detailed review, the team breaks down how DNA is being used to create functional machines by using innovative design strategies, from rigid DNA joints and flexible mechanisms to origami-inspired folding units. The scientists explain how classic principles of macro-scale robotics—such as rigid, compliant and origami robots, —are being adapted for the nanoscale, allowing DNA machines to perform reliable tasks.

 

How to control DNA robots

To make DNA robots "motion", researchers have developed control strategies that enable these machines to behave predictably, even in the chaotic molecular environment. A key focus of the study is how biochemical methods, such as DNA strand displacement, alongside physical stimuli like electric fields, magnetic fields, and light, play a crucial role in directing the precise movement of DNA machines. DNA strand displacement, in particular, allows for the precise programming of these molecular robots using "fuel" and "structure" DNA chains, offering significant potential for controlling their behavior with high accuracy.

 

Applications Beyond the Lab: Medicine, Manufacturing, and More

The implications for DNA robots go far beyond the laboratory. In precision medicine, DNA robots could act as "nano-surgeons" in the body, identifying, targeting, and delivering therapies to specific cells. These robots could even capture viruses like SARS-CoV-2, and the next logical step would be to develop autonomous drug delivery systems.

 

In atomic manufacturing, DNA robots could serve as programmable templates, arranging nanoparticles with sub-nanometer precision. This could pave the way for molecular computers and optical devices that are far more efficient than current technology.

 

Challenges Ahead: Scaling and Integration

However, as the study points out, DNA robots still face significant hurdles. The transition from macroscopic to molecular systems involves overcoming the challenges of Brownian motion and the limitations of scaling. Current designs are often static and isolated, lacking the complexity and functionality needed for broader applications. Additionally, there is still a lack of comprehensive databases on the mechanical properties of DNA structures, and simulation tools for precision remain underdeveloped.

To address these challenges, the team suggests a focus on interdisciplinary innovations. These include developing standardized DNA "parts libraries," integrating AI for dynamic design simulations, and advancing bio-manufacturing techniques. The authors highlight that breakthroughs in manufacturing and design will be crucial for scaling these machines for real-world applications in medicine, manufacturing, and other industries.

 

"The robots of tomorrow won't just be made of metal and plastic," says the research team. "They will be biological, programmable, and intelligent. They will be the tools that allow us to finally master the molecular world."

 

 

Engineered tissue offers hope for children born with ‘missing’ food pipe




University College London





Scientists from Great Ormond Street Hospital (GOSH) and University College London (UCL) have created the first lab‑grown oesophagus - the food pipe - shown to safely replace a full section of the organ and restore normal function, including swallowing, in a growing animal without the need for immunosuppression.

This is a major leap towards personalised regenerative treatments for children born with life threatening oesophageal conditions and could pave the way for translation to other disease areas. Other studies have previously shown parts of this technology, but this is the first time that the full process has been completed with such success.

Published today in Nature Biotechnology the study shows for the first time that a pig donor oesophagus can be decellularised, repopulated with the recipient’s pig’s own cells, and implanted in a growing, large-animal model to restore function without the need for immunosuppression. The eight recipient animals recovered well, developed working swallowing muscles to squeeze food down towards the stomach, with full integration of the engineered tissue within 3 months. Immunosuppression was not needed as the implant was developed using the recipient’s cells and the tissue grew with the animals. [1]

The oesophagus, also known as the ‘food-pipe’, is crucial for nutrition and growth. Children born with long-gap oesophageal atresia (LGOA) have an interrupted oesophagus, with a wide gap between the upper and lower segments. GOSH is a leading site to treat malformations linked to oesophageal atresia (OA), with around 180 babies born with OA, in the UK each year, 10% of which have LGOA.

Children born with LGOA cannot survive without surgery, but the gap is often too large to close immediately after birth. Instead, babies with LGOA typically require a feeding tube placed directly into their stomach, enabling adequate nutrition while their hospital teams develop a treatment plan. The current surgical options are complex and invasive. One approach involves repositioning the stomach or the intestine to bridge the gap, both major operations with significant short- and long-term complications including breathing and gastrointestinal problems, and an unknown long term-cancer risk.

While many children achieve good outcomes, better options with reduced risk of complications are sorely needed for these babies. Thanks to significant funding from Great Ormond Street Hospital Charity (GOSH Charity), including the Oak Foundation, LifeArc and the Francis Crick Institute, this research has been driven forward to identify different and better options, and bring hope to more families.

A personalised, regenerative solution

The first step in this new technology is to create a scaffold, which acts as a tube-shaped base for the new organ. Scientists use a donor pig’s oesophagus, which is very similar to a human’s. Through a process called decellularisation, the donor tissue is carefully stripped of all the pig cells, while keeping the underlying support structure intact.

Next, the scaffold is repopulated with a recipient pig’s muscle cells, taken from a small biopsy. These cells are multiplied in a lab and then injected directly into the scaffold. The graft is then placed in a bioreactor, a special container that pumps vital growth fluids through the tissue for one week. During this time, the cells settle and spread, and they adapt to their new ‘home’. In all, this process takes two months to complete, a timeline compatible with current standard treatment of LGOA.

Research with pigs has now shown very encouraging results, providing a blueprint for human treatment. All eight animals survived the critical first 30 days after transplant. By the 6-month mark, the lab-grown grafts had developed functional muscle, nerves, and blood vessels. This allowed the transplanted oesophagus to contract and move food like a native food pipe. The transplanted animals could eat normally and grow at a healthy rate. While some developed narrowing (strictures), these were successfully managed through endoscopy, mirroring routine human clinical practice. [2]

For the first time ever, this research team were able to map the genes in the structure of the implanted tissue (using a technique called spatial transcriptomics), to show that the genes turned on in the new oesophagus were in line with what would be expected in ‘natural’ tissue. There was also a progressive regeneration of normal oesophageal structures, with a barrier layer, muscle, nerves and blood vessels needed for a functioning oesophagus. The engineered oesophagus was shown to contract, producing movement and pressure with sufficient strength and co-ordination to allow normal swallowing. 

If this technology is adapted for use in humans, different sizes of scaffold, derived from donor pigs, could be stored ready to be developed and personalised for newborns or children of varying sizes and age, whenever needed. Biopsy cells could be taken from the child when the feeding tube is placed and incorporated into the scaffold in exactly the same way as described in this research – creating a personalised graft that would grow with the child and not require immunosuppressants.

Hope for families

Casey Mcintyre from London is a bubbly 2 year-old, who loves his dog, Daisy. You would never be able to tell that he needed so many operations in his short life.

Mum, Silviya (38) said: “We had several scans before Casey was born so we knew he had issues with his food pipe but it was still very worrying to find out he was born with 11cm of it missing. He’s had major operation after major operation as we simply couldn’t get the gap to close using his own tissue. After being referred to GOSH we had the best option at the time – pulling up his stomach to close the ‘gap’ but it’s been a long road and he still has a feeding tube while he develops his swallowing.

“The repeated surgeries have left him with some damage to his vocal cords so he’s developing his speech and noise-making to catch up. Once he’s eating enough through his mouth, we’ll be able to take his tube out.”

Dad, Sean (35) said: “People can never tell Casey has spent half of his life in hospital, and hopefully he won’t remember, but the memories will never leave us.

“We’ve had to learn things as new parents that we never considered would be part of our family life, from feeding him through a stomach tube to what to do if the hospital call with an urgent update in the middle of the night.

“To look at him, he’s just amazing and we are very proud of him. Whatever the team did for him was really a miracle but the idea that there could be one operation early in your child’s life, that could transplant a working piece of oesophagus, and then we could move on would be life changing.”

Professor Paolo De Coppi, NIHR and Nuffield Professor of Paediatric Surgery at UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) and Consultant Paediatric Surgeon at GOSH led the research team. He said: “The oesophagus is a really complex organ, without a blood supply from its own vessels, so it cannot be ‘transplanted’ in the way you might expect. To develop alternatives, it is essential to work with animal models that closely reflect human anatomy and function. In this respect, the pig oesophagus closely resembles the human one. With the success of this research, we hope that we can be successfully offering an engineered tissue alternative to children who desperately need it, within 5 years.”

Dr Marco Pellegrini, Senior Researcher at UCL GOS ICH co-leading the study, said “Our technology could allow us to build a child a new oesophagus, using their own cells, collected in a surgery they are having anyway, combined with a ready-prepared scaffold from pig tissue. Because the graft contains the child’s own muscle progenitor cells, it would be recognised as their own tissue. This means it could grow with them over time, without the risk of rejection and without the need for long-term immunosuppression.”

Dr Natalie Durkin, paediatric surgical registrar and lead author of the study from GOSH and UCL GOS ICH, said: “After successful implantation, our grafts grew, matured and began to function like native tissue. Each one of these steps represents a key milestone in being able to deliver this as a viable treatment option for children in the near future.” Dr Durkin’s work was supported by GOSH Charity via a Lewis Spitz surgical scientist PhD studentship.

Professor De Coppi is Co-Theme Lead of Tissues and Regenerative Medicine at the NIHR GOSH Biomedical Research Centre and went on to say: “For more than 50 years, pig heart valves have been used to extend and save the lives of patients with heart disease, and this technology is now commonplace in cardiac surgery. More recently, xenotransplantation has been explored in humans as a potential solution to organ shortages. In our work, we demonstrate that pig tissue, once stripped of all cellular material, can serve as a scaffold to engineer humanised tissue that is fully biocompatible. I believe we are now standing at a similar new frontier in regenerative medicine.”

Aoife Regan, GOSH Charity's Director of Impact and Charitable Programmes, said: "We are thrilled to see the success of this research, which is offering more hope to children with a highly complex and rare condition, which can significantly affect their quality of life and childhood. At GOSH Charity, we want every child treated at GOSH to have the best chance, and best childhood possible, and providing funding for key projects like this one, demonstrates the impact innovative research can have on those that need it most."

Next steps

The team is now refining the process to generate longer grafts, standardise manufacture and reduce manual steps, and carry out further safety testing. Further studies will focus on tracking the cells on the tissue, optimising blood flow and preparing the therapy for first-in-human trials. The team hope to be able to offer this as a research trial in the next 5 years.

All research at GOSH is supported by the NIHR GOSH Biomedical Research Centre but the NIHR did not directly fund the animal research.


Notes to editors

  1. Full paper: “Functional integration of an autologous engineered oesophagus in a large‑animal model,” Nature Biotechnology, 2026. DOI 10.1038/s41587-026-03043-1. Available to journalists on request or post embargo here: https://www.nature.com/articles/s41587-026-03043-1
  2. Three of the eight animals studies reached the limit number of interventions (endoscopy) allowed by the license of this animal work. This precluded the continued use of these animals in the study and, in accordance with the ‘Animals (Scientific Procedures) Act 1986’, they were humanely euthanised.  
  3. For media inquiries: Lauren.tedaldi@gosh.nhs.uk, media@gosh.nhs.uk,0207 762 6070
  4. An online briefing will be held by the Science Media Centre at 12.15pm UK time on Thursday 19 March 2026. Please contact Fiona Lethbridge lethbridge@sciencemediacentre.org for the joining link.
  5. Photography of the included family can be accessed here: https://we.tl/t-63HJi4gB3K
  6. Professor De Coppi is based at the Zayed Centre for Research, a partnership between UCL and GOSH.

About Great Ormond Street Hospital  

Great Ormond Street Hospital is one of the world’s leading children’s hospitals with the broadest range of dedicated, children’s healthcare specialists under one roof in the UK. The hospital’s pioneering research and treatment gives hope to children from across the UK with the rarest, most complex and often life-threatening conditions. Our patients and families are central to everything we do – from the moment they come through the door and for as long as they need us. All research at Great Ormond Street Hospital NHS Foundation Trust is made possible by the National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre.

About University College London (UCL)

UCL is a global top 10 university, set up in London 200 years ago to offer education for all. Today, we gather 60,000 staff and students, from over 150 countries, to create a unique city within a city – a research and innovation powerhouse that leads the world in subjects spanning the arts, sciences, technology and the humanities. We’ve nurtured 33 Nobel Prize winners, because here, brave ideas have the scale and the support they need to succeed. We are University College London. And here, it can happen. 

UCL turns 200 in 2026. Join us for a year of bicentennial events and celebration. 

www.ucl.ac.uk

 

Genes tied to impulse control play a major role in addiction risk



An analysis of 2.2 million people reveals both shared and substance-specific genetic pathways for addiction risk, showing that vulnerability is rooted more in brain wiring than in any single substance




Rutgers University




Most of the genetic risk for developing a substance use disorder comes from genes that broadly affect how our brains process rewards, regulate impulses and weigh consequences – not from genes that specifically influence substance use disorder or any single drug.

Researchers of a Rutgers Health–led study headed by Holly Poore, a faculty instructor of psychiatry at Rutgers Robert Wood Johnson Medical School, analyzed genetic data from previously published genome-wide association studies totaling more than 2.2 million individuals to understand how genes shape vulnerability to alcohol, tobacco, cannabis and opioid use disorders.

According to the study published in Nature Mental Health, members of the team found genetic risk operates along two main pathways:

  • A broad “behavioral disinhibition” or externalizing pathway, which involves brain systems for reward processing, self-control and risk-taking. Externalizing refers to a heritable pattern of behaviors characterized by difficulty regulating impulses and actions such as impulsivity, attention-deficit/hyperactivity disorder (ADHD), conduct problems and risk-taking behaviors. This pathway cuts across many forms of addiction and related behavioral outcomes.
  • Substance-specific pathways that are more narrowly tied to particular drugs (for example, genes involved in alcohol metabolism or nicotine receptors).

“Most of the genetic predisposition to substance use disorders isn’t about how bodies respond to drugs; it’s about how brains are wired,” said Danielle Dick, director of the Rutgers Addiction Research Center within the Rutgers Brain Health Institute and senior author of the study. “Specifically, risk is mostly related to genes that broadly impact how our brains process rewards and regulate behavior.” 

Dick added, “Those same genes show up across many outcomes – things like ADHD, conduct problems and other risky behaviors – and then layered on top of that are genes that are more specific to each substance. What this paper does, for the first time, is tease apart those pathways at the genomic level.”

Using advanced genomic methods, the researchers analyzed four substance use disorders –alcohol, tobacco, cannabis and opioids – together with related externalizing traits such as ADHD, risk-taking and initiation of substance use. This approach allowed them to identify hundreds of genetic variants associated with a broad externalizing liability as well as genes that were more specific to particular substances.

The researchers found that modeling addiction together with these other traits greatly increased their ability to detect genetic effects without sacrificing the means to see substance-specific signals. Many of the genes linked to the broad liability were involved in brain signaling, reward processing and neural plasticity, while substance-specific genes mapped onto pathways such as alcohol metabolism or nicotinic acetylcholine receptors implicated in tobacco use.

“Traditionally, gene-finding efforts have focused on one disorder at a time,” said Poore, noting how one genome-wide association study is for alcohol, another for tobacco, etc. “But substance use disorders almost never occur in isolation, and decades of twin and family studies have shown that they share a lot of their genetic roots with each other and with other externalizing conditions. By modeling that shared genetic architecture directly, we were able to discover more about both the broad and specific biological pathways that contribute to addiction.”

The researchers also used these genomic discoveries to build polygenic scores, summary measures that combine thousands of genetic variants into a single index of genetic liability. Broad externalizing polygenic scores were especially powerful in predicting risk for multiple substance use disorders, while substance-specific scores provided more precise information about vulnerability to specific drugs, such as alcohol or nicotine.

“From a translational perspective, we can start to think about genetic risk on two levels,” Dick said. “A broader metric can tell us who is generally more vulnerable to addiction and other externalizing problems, while more specific scores can help us understand who is at higher risk for problems with different substances. That doesn’t mean genes determine someone’s destiny, but they can help us identify who might benefit most from targeted prevention or earlier intervention. Genetic risk scores may also help us develop more individualized treatments and recovery plans.”

In addition to mapping genetic risk pathways, the researchers conducted network and drug-target analyses that pointed to potential biological systems and medications that could be leveraged or repurposed for treatment. Many of the genes identified for the broad externalizing pathway overlapped with those implicated in other psychiatric and substance-related disorders, underscoring the shared biology across conditions.

The authors said their analyses were limited to individuals of European ancestry, reflecting the current availability of large-scale genetic datasets, and emphasize the urgent need for more diverse genomic research to ensure findings are relevant and equitable across populations.

“Addiction is incredibly complex, and this study shows just how important it is to look beyond any single substance or single gene,” Poore said. “By understanding the common genetic roots that link substance use disorders with other forms of behavioral disinhibition – as well as the pathways that are specific to alcohol, nicotine, cannabis or opioids – we can build a more complete picture of vulnerability and ultimately support better prevention, intervention and treatment strategies.”

The study was co-authored by an international team of researchers from SUNY Downstate Health Sciences University, the University of California San Diego, Massachusetts General Hospital and Harvard Medical School, Washington University School of Medicine, Emory University, the University of Texas at Austin, Vanderbilt University Medical Center and collaborators from the Collaborative Study on the Genetics of Alcoholism, among others.